



FOUNDATION FUNDING OPPORTUNITIES: JANUARY 7, 2022

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

The MGB **Proposal Deadline Policy** establishes internal deadlines for sponsored research proposals to ensure that submissions meet sponsor criteria and institutional/regulatory requirements. Deadlines are:

- The complete Administrative Components are due to Research Management (RM) on or before the **8th Business Day** by 5 PM.
- The Final (Science) Components are due to RM on or before the **3rd Business Day**.

**Have you updated your MGH Researcher profile?
Go to <https://researchers.mgh.harvard.edu/> today!**

Table of Contents

1. [Diagnostics Accelerator and Target ALS Foundation Biomarker Discovery RFP](#), Alzheimer's Drug Discovery Foundation
2. [Gilead Research Scholars - Liver Disease Program](#), Gilead Sciences, Inc.

1. Diagnostics Accelerator and Target ALS Foundation Biomarker Discovery RFP, Alzheimer's Drug Discovery Foundation **NEW!**

The Diagnostics Accelerator and Target ALS are joining forces to fund biomarker research targeting biomarkers that might be common to disease pathways or pathophysiologies in Alzheimer's disease, FTD and ALS to facilitate biomarker discovery and validation. In doing so, the Diagnostics Accelerator and Target ALS aim to drive towards an improved understanding of the heterogeneity of these neurodegenerative diseases and offer potential solutions for differential diagnosis.

Projects will be funded via two mechanisms:

- Option 1: As a grant through Target ALS Foundation



Do you want to learn more about identifying external funding opportunities? Please [click here](#) to request a research consultation with **Amy Robb** or see ECOR's website for information on the [Pivot database](#).

- Option 2: As a mission-related investment from the Diagnostics Accelerator at the ADDF

Funding Priorities

Modalities: Protein and molecular biomarkers in blood and other peripheral fluids, including saliva, urine and ocular biomarkers are encouraged. Digital biomarker approaches are also of high interest. The development of CSF and neuroimaging biomarkers will not be considered for this program; however, we encourage the use of these modalities to validate proposed biomarkers. Proposals to support or create longitudinal cohorts will not be considered, but we welcome applications utilizing existing patient cohorts. In addition, it is expected that applicants will have some supporting data collected to support their proposed research and/or an existing prototype device or app developed in the case of digital biomarkers, commensurate with the project stage and justified budget as described below.

Biomarker targets: Proposed approaches will be evaluated on biological plausibility linking the biomarker to disease pathophysiology. Examples of target areas of interest include:

Peripheral Biomarkers of Interest

- Misfolded proteins (e.g., TDP-43) and related biological pathways
- Dipeptide repeats
- Neuroinflammation
- Progranulin
- Ocular biomarkers (e.g., retinal vasculature, choroidal thickness, retinal nerve fiber layer thinning etc.)

Digital Symptom Domain of Interest

- Gait and gross motor movement
- Sleep patterns and characteristics
- Strength (e.g., handheld dynamometry)
- Speech and swallowing
- Instrumental Activities of Daily Living (IADL)
- Fatigue

Eligibility requirements (partial list):

- Each collaborative project must include two to four investigators with at least one based at a pharmaceutical/biotechnology company working around a common biomarker.

Citizenship: Unrestricted

Award Amount:

- Option 1: \$600,000 paid over 2 years
- Option 2: \$500,000 for 1 year

Indirect Costs: None

LOI Deadline: March 2, 2022

Research Management Deadline: April 27, 2022

(Invited) Proposal Deadline: May 6, 2022

Website: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-accelerator-and-target-als-foundation-biomarker-discovery-rfp>

2. Gilead Research Scholars - Liver Disease Program, Gilead Sciences, Inc.

The program is designed to support basic and clinical research in the field of liver disease. We strongly encourage proposals in clinical research.

Areas of research may include, but are not limited to:

- Chronic viral hepatitis
- End-stage liver disease and its complications
- Non-viral chronic liver diseases
- Basic, clinical, and translational research related to liver disease
- Health economics outcomes research relating to liver disease

Eligibility requirements (partial list):

- Applicants must anticipate receiving a faculty appointment or an assistant professorship within 3 years, in association with a research institution in one of the eligible countries
- Have a strong career interest in liver disease
- Have a research mentor with extensive experience in the field of liver disease

Citizenship: Canada or Europe or United States

Award Amount: \$130,000 paid over 2 years

Indirect Costs: 10%

Research Management Deadline: April 21, 2022

Application Deadline: May 1, 2022

Website: https://researchscholars.gilead.com/en/liver_disease_portal